News

Phlow Corp. Receives HHS Small Business Prime Contractor of the Year Award

The U.S. Department of Health and Human Services (HHS), recently awarded Phlow Corp. the Office of Small and Disadvantaged Business Utilization (OSDBU), Small Business Prime Contractor of the Year Award. Phlow Corp. is a U.S.-based, public benefit corporation committed to solving America’s broken essential medicine supply chain. This award recognizes Phlow for its performance during the previous fiscal year on its contract with HHS.

“We are honored to receive this recognition from HHS as we work together to reliably supply affordable, high-quality, essential medicines through U.S.-based advanced manufacturing processes,” said Eric Edwards, M.D., Ph.D., co-founder, President, and CEO of Phlow. “We are thrilled to continue expanding our existing relationship with the U.S. Government to create a resilient and sustainable essential medicines supply chain that will benefit all Americans.”

Phlow’s vision is to make the U.S. a country where every human being has access to the essential medicines necessary to sustain life and conquer disease. Throughout 2020 and 2021, Phlow has worked toward strengthening the U.S. essential medicines supply chain by offering a novel, resilient, end-to-end solution that is U.S.-based, comprehensive, and fully integrated.

The U.S. Government and Phlow recognize the importance of enhancing domestic manufacturing as well as providing diversity in the essential medicine supply chain by leveraging private sector partnerships to achieve essential medicine supply chain resilience. With contract funding support from the Biomedical Advanced Research and Development Authority (BARDA), part of the office of Assistant Secretary for Preparedness and Response (ASPR) at HHS, Phlow is currently developing a comprehensive advanced development and manufacturing infrastructure, including a Strategic Active Pharmaceutical Ingredient Reserve (“SAPIR”), intended to help ensure the U.S. has an uninterrupted supply of affordable essential life-saving medicine ingredients that can be rapidly converted to finished essential medicines to meet increasing demands due to supply chain disruptions whether from trade challenges, international conflicts, natural disasters, or future public health emergencies.

Recent News

04/02/2025

VCU startup wins $800k grant to propel its infection-fighting surgical gel

With an innovation that could advance brain and spinal surgeries, a Virginia Commonwealth University startup has received an $800,000 state grant to support development of its infection-fighting gel. Pascal Medical Corp. is one of four grant recipients to receive awards from Virginia Catalyst, a nonprofit created by the General Assembly and funded by the state’s general

04/02/2025

Quoin Pharmaceuticals Announces Additional Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study and Approval to Initiate Testing of a Second Pediatric Patient

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announces additional highly positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome (NS) study. After 6 weeks of continued whole body application

04/02/2025

Charlottesville Angel Network Celebrates 10 Years, Surpasses $20 Million in Investments

The Charlottesville Angel Network (CAN), a group of accredited investors dedicated to supporting early-stage ventures, proudly marks its 10th anniversary this month. Since its inception, CAN angel investor members have invested more than $20 million in nearly 80 startups, fostering innovation both locally and beyond. Reflecting on a decade of achievements, CAN has realized returns